SPG11 Mutations Associated With a Complex Phenotype Resembling Dopa-Responsive Dystonia

Subhashie Wijemanne, MD, MRCP,[1] Joshua M. Shulman, MD, PhD,[1,2,3,4] Joohi Jimenez-Shahed, MD,[1] Daniel Curry, MD,[5] Joseph Jankovic, MD[1,*]

Abstract: Background: The aim of this study was to describe a case of hereditary spastic paraplegia (HSP) resulting from *SPG11* mutations, presenting with a complex phenotype of dopa-responsive dystonia (DRD), diagnosed using whole exome sequencing (WES). HSP resulting from *SPG11* typically presents with spasticity, cognitive impairment, and radiological evidence of thin corpus callosum. Initial presentation with DRD has not been previously reported on. Methods: This 11-year-old boy with delay in fine motor skills, presented at 8 years of age with progressive, generalized dystonia with diurnal variation, bradykinesia, and stiff gait. There was marked improvement in dystonia with levodopa, but he soon developed wearing-off phenomenon and L-dopa-induced dyskinesia. Family history was unremarkable. Results: Brain MRI showed thinning of the anterior corpus callosum with periventricular white matter changes. ^{123}I-ioflupane single-photon emission coupled tomography showed bilateral severe presynaptic dopamine deficiency. WES identified transheterozygous allelic variants in the *SPG11* on chromosome 15, including a truncating STOP mutation (p.E1630X) and a second heterozygous coding variant (p.L2300R). Dystonia improved with globus pallidus internus (GPi) DBS surgery. Conclusions: HSP resulting from *SPG11* should be considered in the differential diagnosis of a patient presenting with DRD, parkinsonism, and spasticity. This case expands the HSP genotype and phenotype. GPi DBS may be a therapeutic option in selected patients.

Hereditary spastic paraplegia (HSP) is a clinically and genetically heterogeneous neurodegenerative disorder characterized predominantly by progressive weakness and spasticity of the lower limbs.[1] HSP can present with spasticity alone (uncomplicated) or spasticity associated with other neurological and non-neurologic features (complicated or complex). To date, 72 different spastic gait disease loci have been identified, and 55 spastic paraplegia genes have already been cloned, which include autosomal-dominant, autosomal-recessive, and X-linked forms of HSP.[2]

HSP resulting from *SPG11* mutations is a common cause of autosomal recessive HSP, which typically presents clinically with spasticity, cognitive impairment, and peripheral neuropathy. Radiologically it is characterized by thinning of the corpus callosum (TCC) and periventricular white matter changes.[3,4] However, there is increasing recognition that mutations in *SPG11* can cause heterogeneous clinical manifestations, includ-

ing juvenile-onset parkinsonism[3,5–7] and, rarely, dystonia (Table 1).[3,5,7–10] Other HSPs can rarely have dystonia or parkinsonism.[2]

Dopa–responsive dystonia (DRD) is characterized by childhood-onset dystonia, diurnal fluctuation of symptoms, and a dramatic response to levodopa therapy.[11] Parkinsonian features may appear later in the course of the disease and in adult family members. A minority of patients may have hyperactive deep tendon reflexes and an apparent extensor plantar response.[12] The majority of reported cases of DRD have been a result of mutations in genes that encode enzymes involved in the endogenous dopamine biosynthesis pathway, such as GTP cyclohydrolase (GCH-1) deficiency, as well as tyrosine hydroxylase (TH) and sepiapterin reductase deficiency.[13] There are other rare causes of the DRD phenotype, which include 6-pyruvoyl–tetrahydropterin synthase deficiency,[14] *PARK2*,[15] *SCA3*,[16] and *ATM*.[17]

[1]Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas, USA; [2]Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA; [3]Department of Neuroscience, Baylor College of Medicine, Houston, Texas, USA; [4]Jan and Dan Duncan Neurological Research Institute, Texas Children's Hospital, Houston, Texas, USA; [5]Texas Children's Hospital, Houston, Texas, USA

Correspondence to: Dr. Joseph Jankovic, Department of Neurology, Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine, 7200 Cambridge, 9th Floor, MS : BCM 609, Houston, TX 77030, USA; E-mail: josephj@bcm.edu

TABLE 1 Summary of reported cases of SPG11 mutation associated with dystonia

Case	Mutation 1	Mutation 2	Age at Evaluation /Sex	Presenting Symptom(s)	Age of Onset	Clinical Features	Parkinsonism	Dystonia	Brain Imaging
Vanderver et al.[8] Case 4	c.4222insA; p.1426X [STOPAA1426]	c.4777delA; p.1606X [STOPAA1606]	25 F	Impaired balance	12	Spastic paraparesis, distal muscular atrophy, weakness of the hands, urinary incontinence, macular flecks involving the macular and perimacular area, mild sensory neuropathy	Rigidity of upper extremities, bradykinesia	Dystonia of toes	TCC and periventricular white matter abnormalities
Yoon et al.[9] Case 8	c.3664_3665insT (p.Lys1222IlefsX15)	r.4667_4774del	17 F	Gait abnormality, poor coordination	6	Learning disability, bladder dysfunction, falls, speech abnormalities, cognitive decline	Bradykinesia	Dystonia(not specified)	TCC
Stevanin, et al.[3] FSP870-17	c.733_734delAT, p.M245VfsX246	c.733_734delAT, p.M245VfsX246	25/M	Stiff legs	15	Cognitive impairment, pes cavus, renal lithiasis	None	Facial dystonia	Not available
Stevanin et al.[3] FSP870-20	c.733_734delAT, p.M245VfsX246	c.733_734delAT, p.M245VfsX246	28/M	Weakness legs	17	Severe weakness, intellectual disability	None	Dystonia of face and tongue	Not available
Paisan-Ruiz, et al.[7]	Frameshift p.His235ArgfsX12	p.His235ArgfsX12	27 M	Postural and writing tremor	14	Walking difficulties with imbalance, speech problems, and slowness, progressively stiff and he complained of leg weakness and falls, brisk reflexes, ankle clonus	Facial hypomimia, writing tremor, axial rigidity and bradykinesia	Laryngeal dystonia, hand dystonia	MRI brain generalized atrophy with a TCC. DaT-SPECT decreased bilateral putaminal and caudate uptake
Guidubaldi et al.[5]	c.3664insT (p.KI222IfsX13)	c.633insG (p.E2I11GfsX36)	32 F	Abnormal gait and progressive rigidity	14	Dysarthria, postural instability, severe spastic paraparesis, generalized brisk reflexes, and bilateral pes cavus with extensor plantar response, mild cerebellar signs, mild dysphagia, and urinary urgency, memory and executive functions	Wearing-off phenomenon and "peak-dose" dyskinesias, featuring facial, bilateral resting tremor, and mild bradykinesia	OFF dystonia. No further description	Pronounced TCC, diffuse cortical cerebral and mild cerebellar atrophy, and hyperintense T2-weighted lesions in periventricular regions. DaT-SPECT was consistent with severe, bilateral symmetrical nigrostriatal loss
Paisan-Ruiz et al.[10] Family 4	Sequence variant p.A59V of unknown significance. Identified as a heterozygote in one control		24 F	Walking difficulty	13	Axonal neuropathy, cognitive impairment, brisk reflexes, extensor plantar, severe ataxia	None	Severe dystonia in the limbs and torticollis, spastic dysarthria, ophthalmoplegia, hypometric saccades, slow tongue	Borderline TCC and cerebellar atrophy

Here, we describe a unique case of HSP associated with *SPG11* mutations, diagnosed by whole exome sequencing (WES), that presented with a phenotype of dopa-responsive dystonia, spasticity, and parkinsonism.

Case Report

An 11-year-old boy was initially evaluated at our clinic because of abnormal posturing of the limbs. He was born full term, but his birth was complicated by fetal distress and bilateral pneumothorax, followed by chronic interstitial pulmonary dysfunction, which improved over the next few years. He had some delay in motor milestones, but with intensive physical therapy, he was able to run and walk well, although he continued to have mild impairment in fine motor function.

At 8 years of age, he started to drag his left leg while walking and developed similar symptoms in the right leg a few weeks later. He had abnormal posturing of the left arm characterized by abduction of the shoulder as well as flexion at the elbow with the arm behind the head. Subsequently, he developed abnormal posturing of the right arm. Jerky tremor was also noticed bilaterally in the hands while reaching to grab objects. Over time, he also developed bilateral upper-extremity rest tremor. His gait became stiff and he developed postural instability and near falling. At the beginning the patient's parents noticed marked diurnal variation in his symptoms: He was generally well upon awakening and became progressively worse by the end of the day. His symptoms also improved after a nap. Within 1 year, his condition progressed such that he became increasingly dependent on a wheelchair. He also developed urinary incontinence. In addition to progressive motor and autonomic symptoms, he exhibited attention deficit hyperactivity disorder (ADHD), obsessive-compulsive disorder, and anxiety. In 2011, at the age of 9 years, he was suspected to have DRD and was given a trial of carbidopa/L-dopa (25/100 mg three times a day) resulting in marked improvement in all motor symptoms. However, within a few months, he experienced wearing off, requiring increased frequency of L-dopa doses to four times daily.

The patient was first evaluated at our clinic in 2013 at the age of 11. He was examined 2 hours after the last dose of L-dopa while in the ON state (see Video 1). There was evidence of irregular jerky movements of the head and trunk at rest, which worsened with movement. He also had irregular jerky movements of both arms on finger-to-nose maneuver and in posture holding, suggestive of dystonic tremor. He had dystonia in both arms, worse on the left with flexion of the wrist and fingers, and extension of the fingers on the right. Fine finger movements were slow and deliberate without decrementing amplitude. There was extension of the left leg with eversion and slight extension of the foot, especially at rest. Five and a half hours after the last dose of L-dopa while in the OFF state (see Video 1), the patient had marked worsening of dystonia with moderate left torticollis and retrocollis at rest. Dystonia was also worse in the extremities, especially in the right leg. He also had mild intermittent opisthotonic

extension of the trunk, which limited his gait and resulted in near falls in the absence of support. Dystonic tremors were more pronounced when off medications. Reflexes were brisk, particularly in the lower extremities with 6 to 8 beats of ankle clonus and bilateral extensor plantar response. There was no ataxia or dysmetria.

The patient continued to experience wearing off, and when the L-dopa dose was further increased, he developed L-dopa-induced choreiform peak-dose dyskinesia involving the face and arms (see Video 1). He had similar dyskinesia while on trihexyphenidyl, which was later discontinued. Ropinirole and amantadine were also tried, but did not provide meaningful benefit. The duration of L-dopa response became progressively shorter and his OFF periods were characterized by progressively worse generalized dystonia as well as speech difficulty, palpitations, anxiety, and nausea. He denied any sensory symptoms in the legs, and the sensory examination was normal.

A neuropsychology evaluation performed 2 years before the onset of motor symptoms met criteria for a diagnosis of ADHD and impaired verbal IQ. Comprehensive retinal examination by an ophthalmologist was unremarkable. A maternal great grandmother had Parkinson's disease in her 70s, but there was no other family history of dystonia or parkinsonism. The parents, who are of Western European descent, are healthy and there is no known history of consanguinity in the family. He has one younger brother who is healthy.

Cerebrospinal fluid (CSF) neurotransmitter assessment (performed before commencement of dopaminergic medications) revealed low levels of both tetrahydrobiopterin (BH4) at 7 nmol/L (9–40 nmol/L) and homovanillic acid (HVA) at 204 nmol/L (218–852 nmol/L), but normal levels of 5-hydroxyindoleacetic acid (5-HIAA) 133 nmol/L (range, 66–338), neopterin 16 nmol/L (range, 7–40), and 3-O-methyldopa 12 nmol/L (<100 nmol/L). Genetic testing for Friedreich's ataxia was negative. EEG did not show any epileptiform activity. Brain MRI showed periventricular hyperintense T2-weighted lesions and TCC, especially the anterior half (Fig. 1A–C). He underwent ^{123}I-ioflupane single-photon emission coupled tomography (DaT-SPECT), which showed essentially absent tracer uptake in bilateral putamina with marked reduced uptake in the caudate nuclei, with slightly greater reduction in the left caudate nucleus compared to the right (Fig. 1D).

Given the unusual and complex phenotype in this case, the number of potentially contributory genetic syndromes, as well as the remote possibility of a novel underlying condition, blood was sent for WES, rather than targeted genetic testing. WES was performed by the Medical Genetics Laboratories (MGL) at Baylor College of Medicine (BCM; Houston, TX), which is certified by the College of American Pathologists and the Clinical Laboratory Improvement Amendments. Discovered variants are interpreted in accordance with guidelines from the American College of Medical Genetics and Genomics (ACMG). The analysis pipeline and interpretation of WES by the BCM-MGL for use in clinical practice has been previously reported on in detail and validated in a large, clinical case series.[18]

Figure 1 (A and B) Axial T2 fluid-attenuated inversion recovery showing increased T2 signal in the periventricular white matter. (C) Sagittal T1-marked thinning of the anterior half of the corpus callosum. (D) DaT-SPECT showing essentially absent tracer activity in bilateral putamina and reduced uptake in caudate with slightly greater reduction in left caudate nucleus, compared to the right. (E) 1–3: Sedated resting-state fMRI of motor function was atypical in that bilateral leg network and also includes bilateral hand and putamen. (F) 1–3: Sedated resting-state fMRI of motor function was atypical in that bilateral sensory-face area includes the putamen.

Genetic analysis

WES of our patient revealed a mutation, c.4888G>T (p.E1630X), in the *SPG11* gene on chromosome 15:4881468, predicted to introduce a premature STOP within exon 28, and consistent with a pathogenic allele based on established guidelines.[19] A second heterozygous variant in *SPG11* c.6899T>G (rs371334506, chromosome 15: 44858152) was also discovered. This is a rare missense variant within exon 38, predicted to result in a leucine to arginine change at position 2300. Based on publicly available exome data (http://evs.gs.washington.edu/EVS/), this variant has previously been observed only once in 8,596 control chromosomes from individuals of European-American ancestry (minor allele frequency: ~0.01%). Both variants were confirmed by Sanger sequencing in our patient. In addition, targeted *SPG11* sequencing of both parents demonstrated unambiguously that the p.E1630X and p.L2300R alleles were inherited from the father and mother, respectively, establishing these variants in the transheterozygous configuration in our patient. Although the p.L2300R change is classified as a variant of unknown clinical significance (VUS) based on ACMG guidelines, it is predicted to be damaging by the sorting intolerant from tolerant technique[20] and probably damaging by PolyPhen–2,[21] two validated algorithms for predicting the consequences of protein amino acid substitutions.[19] WES did not identify a *GCH-1* mutation.

Notably, another heterozygous variant of unknown clinical significance, in the *MTPAP* gene c.410A>T(p.Q137L), was also discovered in our patient, which is a novel variant, based on public databases. Defects in this gene cause autosomal-recessive spastic ataxia 4 (p.SPAX4) MIM:613672. A second candidate variant or mutation was not discovered, consistent with the recessive nature of this condition, although the presence of a deletion or duplication cannot be definitively ruled out based on the WES results. Furthermore, our patient did not demonstrate ataxia, a core clinical feature of this rare genetic disorder, described to date only in a single large Amish family.[22]

Our patient continued to have progressively shorter response to L-dopa over time and additionally developed intermittent episodes of generalized dystonia associated with speech difficulty, diaphoresis, and severe anxiety. These periods occurred during medication wearing off, which were very disabling for the patient and affected his overall quality of life. On the other hand, bothersome L-dopa–induced choreiform dyskinesia (see Video 1) limited the frequent dosing of L-dopa. Although previous experience is lacking, DBS surgery was considered a potential treatment option for management of generalized dystonia.

The response to DBS was assessed using the Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS).[23] BFMDRS score before surgery in the OFF-state was 24.5 and in the ON-state was 13.5. The patient's performance on neuropsychology testing was limited by worsening of dystonia at first and then by development of dyskinesia during the testing period. Before surgery, he underwent fluorodeoxyglucose PET, which was normal, and resting-state functional MRI (fMRI) showed evidence of cortical-basal ganglia overconnectivity (Fig. 1E1–3 and F1–3).

He underwent bilateral globus pallidus internus (GPi) DBS surgery in June 2014 with microelectrode recordings for target localization. Two months after implantation of the DBS and after completing 2 programming sessions, he showed a moderate reduction in the number and severity of dystonic episodes related to the wearing-off periods. The BFMDRS off medications with the DBS turned on was 9.

Discussion

We discovered a novel, compound heterozygous genotype at the *SPG11* gene as the most likely cause of the clinical phenotype in our patient. Of the two *SPG11* allelic variants identified, the premature nonsense variant (p.E1630X) is a potentially

truncating mutation and is pathogenic based on ACMG guidelines.[19] Whereas the p.L2300R variant, by contrast, is formally classified as a VUS, this rare missense change is found to be deleterious based on two independent algorithms. Furthermore, Sanger sequencing of the parents established these alleles to be in the transheterozygous configuration, consistent with the autosomal-recessive inheritance of *SPG11*-associated HSP. Finally, as discussed below, we believe the phenotypic overlap between our case presentation and previous reports establishes HSP resulting from *SPG11* mutations as the most likely molecular diagnosis. To date, at least 127 distinct mutations in the *SPG11* gene have been reported.[24] *SPG11* (MIM610844) maps to chromosome 15q13–15 and encodes spatacsin, a protein of unknown function. The protein has been associated with cytoskeleton, endoplasmic reticulum, and vesicles involved in protein trafficking, suggesting a potential role in axonal transport.[25,26] Spatacsin has also been identified as a component of Lewy bodies and glial cytoplasmic inclusions.[27] This new compound heterozygous mutation in our patient broadens the potential allelic spectrum in *SPG11*-associated HSP.

The mean age at onset of HSP resulting from *SPG11* mutations is 12 years (range, 2–23) with initial presentation of difficulty with ambulation (57%), which may be preceded by intellectual disability in up to 19% of patients.[25] Our case expands the clinical phenotype associated with *SPG11* mutations to include predominantly early dystonia with diurnal fluctuation and robust L-dopa–responsive dystonia mimicking a DRD phenotype. Additionally, a rapidly progressive course demonstration of "wearing-off phenomenon" and the occurrence of L-dopa-induced dyskinesia (see Video 1) within a few months of starting L-dopa therapy were unusual. The DaT-SPECT imaging was abnormal (Fig. 1D), indicating presynaptic dopamine neuronal dysfunction, which is a hallmark of neurodegenerative parkinsonism. L-dopa-induced dyskinesia has been previously reported in a case of juvenile-onset parkinsonism resulting from *SPG11*[5] (Table 1), and there are several reported cases of *SPG11* mutations[5–7] with parkinsonism having abnormal DaT-SPECT. However, not all cases of *SPG11* deficiency are accompanied by parkinsonism, and it is likely a unique phenotypic variant of this condition. By contrast, DaT-SPECT is negative in cases of DRD resulting from GCH-1 and TH deficiency, consistent with preserved striatal dopaminergic presynaptic nerve terminals.[28–30] TCC with periventricular white matter change, as observed on MRI in our patient, is most commonly observed in *SPG11* mutations; however, it can be also observed in *SPG15* and, rarely, in cases with *SPG 21*, *SPG35*, *SPG48*, and *SPG54*.[31]

Previous studies have also found CSF neurotransmitter metabolite abnormalities in *SPG11*. One study evaluating neurotransmitter metabolites in 4 patients with *SPG11* mutations showed low concentration of HVA (3 of 4), which is the main metabolite in the catabolic pathway of dopamine, and low concentration of BH4 (3 of 4) and normal neopterin (all 4), similar to our patient. 5-HIAA was normal in 3 of 4 patients.[8] The mechanism leading to neurotransmitter abnormalities in *SPG11* patients is not known and further studies are needed.

WES, which played a key role in our diagnosis of this patient, is finding increasing clinical utility in patients with presumed genetic syndromes.[18,32,33] Given the unusual, complex clinical presentation, including dystonia and parkinsonism, and the known genetic heterogeneity underlying the suspected diagnosis of DRD, the alternative to WES would have been to pursue piecemeal testing for numerous individual gene mutations and/or testing for large panels of candidate genes causing overlapping syndromes. In retrospect, WES was the most efficient, cost-effective option for initial genetic testing in such a circumstance. The increasing availability of WES in clinical practice will undoubtedly broaden the known clinical and etiological spectrum of DRD. Our case supports the notion that DRD is a syndrome with multiple etiologies and clinical phenomenologies.

To our knowledge, this is the first reported case of *SPG11* gene mutations treated with GPi-DBS surgery. Our results show that, in the short term, DBS surgery can be effective in improving generalized dystonia, reducing the wearing-off periods and thereby reducing the bothersome dystonic episodes. We will continue to follow this patient to establish the long-term response to DBS surgery.

In conclusion, HSP resulting from *SPG11* mutations should be considered in the differential diagnosis of a patient presenting with DRD, parkinsonism, and spasticity. This unusual case expands the clinical phenotypes associated with this form of HSP and further adds to the heterogeneous genetic causes of DRD. DBS surgery may be an option in selected cases.

Author Roles

Acknowledgments

Disclosures

References

1. Fink JK. Hereditary spastic paraplegia. *Curr Neurol Neurosci Rep* 2006;6:65–76.

2. Lo Giudice T, Lombardi F, Santorelli FM, Kawarai T, Orlacchio A. Hereditary spastic paraplegia: clinical-genetic characteristics and evolving molecular mechanisms. *Exp Neurol* 2014;261C:518–539.

3. Stevanin G, Azzedine H, Denora P, et al. Mutations in SPG11 are frequent in autosomal recessive spastic paraplegia with thin corpus callosum, cognitive decline and lower motor neuron degeneration. *Brain* 2008;131:772–784.

4. Siri L, Battaglia FM, Tessa A, et al. Cognitive profile in spastic paraplegia with thin corpus callosum and mutations in SPG11. *Neuropediatrics* 2010;41:35–38.

5. Guidubaldi A, Piano C, Santorelli FM, et al. Novel mutations in SPG11 cause hereditary spastic paraplegia associated with early-onset levodopa-responsive parkinsonism. *Mov Disord* 2011;26:553–556.

6. Anheim M, Lagier-Tourenne C, Stevanin G, et al. SPG11 spastic paraplegia. A new cause of juvenile parkinsonism. *J Neurol* 2009;256:104–108.

7. Paisan-Ruiz C, Guevara R, Federoff M, et al. Early-onset L-dopa-responsive parkinsonism with pyramidal signs due to ATP13A2, PLA2G6, FBXO7 and spatacsin mutations. *Mov Disord* 2010;25:1791–1800.

8. Vanderver A, Tonduti D, Auerbach S, et al. Neurotransmitter abnormalities and response to supplementation in SPG11. *Mol Genet Metab* 2012;107:229–233.

9. Yoon G, Baskin B, Tarnopolsky M, et al. Autosomal recessive hereditary spastic paraplegia-clinical and genetic characteristics of a well-defined cohort. *Neurogenetics* 2013;14:181–188.

10. Paisan-Ruiz C, Nath P, Wood NW, Singleton A, Houlden H. Clinical heterogeneity and genotype-phenotype correlations in hereditary spastic paraplegia because of Spatacsin mutations (SPG11). *Eur J Neurol* 2008;15:1065–1070.

11. Segawa M, Hosaka A, Miyagawa F, Nomura Y, Imai H. Hereditary progressive dystonia with marked diurnal fluctuation. *Adv Neurol* 1976;14:215–233.

12. Asmus F, Gasser T. Dystonia-plus syndromes. *Eur J Neurol* 2010;17(Suppl. 1):37–45.

13. Clot F, Grabli D, Cazeneuve C, et al. Exhaustive analysis of BH4 and dopamine biosynthesis genes in patients with Dopa-responsive dystonia. *Brain* 2009;132:1753–1763.

14. Hanihara T, Inoue K, Kawanishi C, et al. 6-Pyruvoyl-tetrahydropterin synthase deficiency with generalized dystonia and diurnal fluctuation of symptoms: a clinical and molecular study. *Mov Disord* 1997;12:408–411.

15. Khan NL, Graham E, Critchley P, et al. Parkin disease: a phenotypic study of a large case series. *Brain* 2003;126:1279–1292.

16. Wilder-Smith E, Tan EK, Law HY, Zhao Y, Ng I, Wong MC. Spinocerebellar ataxia type 3 presenting as an L-DOPA responsive dystonia phenotype in a Chinese family. *J Neurol Sci* 2003;213:25–28.

17. Charlesworth G, Mohire MD, Schneider SA, Stamelou M, Wood NW, Bhatia KP. Ataxia telangiectasia presenting as dopa-responsive cervical dystonia. *Neurology* 2013;81:1148–1151.

18. Yang Y, Muzny DM, Reid JG, et al. Clinical whole-exome sequencing for the diagnosis of mendelian disorders. *N Engl J Med* 2013;369:1502–1511.

19. Richards CS, Bale S, Bellissimo DB, et al. ACMG recommendations for standards for interpretation and reporting of sequence variations: revisions 2007. *Genet Med* 2008;10:294–300.

20. Ng PC, Henikoff S. SIFT: predicting amino acid changes that affect protein function. *Nucleic Acids Res* 2003;31:3812–3814.

21. Ramensky V, Bork P, Sunyaev S. Human non-synonymous SNPs: server and survey. *Nucleic Acids Res* 2002;30:3894–3900.

22. Crosby AH, Patel H, Chioza BA, et al. Defective mitochondrial mRNA maturation is associated with spastic ataxia. *Am J Hum Genet* 2010;87:655–660.

23. Burke RE, Fahn S, Marsden CD, Bressman SB, Moskowitz C, Friedman J. Validity and reliability of a rating scale for the primary torsion dystonias. *Neurology* 1985;35:73–77.

24. Zhao W, Zhu QY, Zhang JT, et al. Exome sequencing identifies novel compound heterozygous mutations in SPG11 that cause autosomal recessive hereditary spastic paraplegia. *J Neurol Sci* 2013;335:112–117.

25. Stevanin G, Santorelli FM, Azzedine H, et al. Mutations in SPG11, encoding spatacsin, are a major cause of spastic paraplegia with thin corpus callosum. *Nat Genet* 2007;39:366–372.

26. Murmu RP, Martin E, Rastetter A, et al. Cellular distribution and subcellular localization of spatacsin and spastizin, two proteins involved in hereditary spastic paraplegia. *Mol Cell Neurosci* 2011;47:191–202.

27. Kuru S, Yoshida M, Tatsumi S, Mimuro M. Immunohistochemical localization of spatacsin in alpha-synucleinopathies. *Neuropathology* 2013;34:135–139.

28. Rajput AH, Gibb WR, Zhong XH, et al. Dopa-responsive dystonia: pathological and biochemical observations in a case. *Ann Neurol* 1994;35:396–402.

29. Jeon BS, Jeong JM, Park SS, et al. Dopamine transporter density measured by [123I]beta-CIT single-photon emission computed tomography is normal in dopa-responsive dystonia. *Ann Neurol* 1998;43:792–800.

30. Naumann M, Pirker W, Reiners K, Lange K, Becker G, Brucke T. [123I]beta-CIT single-photon emission tomography in DOPA-responsive dystonia. *Mov Disord* 1997;12:448–451.

31. Pensato V, Castellotti B, Gellera C, et al. Overlapping phenotypes in complex spastic paraplegias SPG11, SPG15, SPG35 and SPG48. *Brain* 2014;137:1907–1920.

32. Bettencourt C, Lopez-Sendon J, Garcia-Caldentey J, et al. Exome sequencing is a useful diagnostic tool for complicated forms of hereditary spastic paraplegia. *Clin Genet* 2013;85:154–158.

33. Bainbridge MN, Wiszniewski W, Murdock DR, et al. Whole-genome sequencing for optimized patient management. *Sci Transl Med* 2011;3:87re83.

Supporting Information

A video accompanying this article is available in the supporting information here.

Video 1. The first part of the video, taken during the ON state, shows minimal hand dystonia and spastic gait. The second segment, recorded during the OFF state, showed prominent generalized dystonia with moderate left torticollis, retrocollis at rest, bilateral arm and right leg dystonia, dystonic tremor, and bradykinesia. The third segment shows generalized, predominantly choreic, L-dopa-induced dyskinesia.